Hospital
Greenwich Hospital
Greenwich Hospital was paid $46.42M by Medicaid between Jan 2018 and Dec 2024, across 381 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 16% of everything it billed.
33Billing provider infoGREENWICH HOSPITAL
GREENWICH, CT 06830
GREENWICH, CT 06830
33aNPI1609846088assigned 01/26/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$46.42M
24GClaims1,601,284
24DCodes billed381
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Connecticut
Rank by total paid#9 of 18
Median peer was paid$15.60M
This provider vs. median3.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WRINN, JACQUELINE controls 12+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 171,694 | $4.41M | |
| 2019 | 187,223 | $5.26M | |
| 2020 | 174,421 | $4.89M | |
| 2021 | 252,245 | $7.11M | |
| 2022 | 280,878 | $8.45M | |
| 2023 | 289,426 | $8.07M | |
| 2024incomplete | 245,397 | $8.23M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 16% | 71,914 | 54,907 | $7.52M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 24,609 | 20,603 | $6.36M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 12% | 10,639 | 8,954 | $5.34M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.7% | 22,675 | 19,370 | $4.52M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 6.5% | 48,615 | 13,750 | $3.00M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.1% | 21,972 | 18,447 | $1.43M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.0% | 12,226 | 9,817 | $1.38M |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.4% | 9,504 | 7,899 | $1.10M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.4% | 3,471 | 3,144 | $673K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.2% | 3,508 | 3,032 | $550K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 4,431 | 2,511 | $521K |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | 1.1% | 114 | 110 | $489K |
369 more codes
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,315 | $463K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 38,082 | $459K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 3,347 | $439K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 4,172 | $402K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 3,826 | $365K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,689 | $365K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 17,810 | $363K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,441 | $350K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,826 | $349K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,294 | $336K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,581 | $326K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 4,656 | $325K |
| J0485 | Injection, belatacept, 1 mg | <1% | 908 | $308K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 2,327 | $299K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 6,878 | $279K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,470 | $254K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,317 | $212K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,893 | $206K |
| G0378 | Hospital observation service, per hour | <1% | 5,919 | $203K |
| 76641 | <1% | 2,284 | $202K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 5,681 | $196K |
| 76770 | <1% | 1,416 | $172K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 5,532 | $168K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 7,761 | $168K |
| 80053 | Comprehensive metabolic panel | <1% | 18,687 | $164K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,022 | $158K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 872 | $158K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 9,717 | $155K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 17,515 | $155K |
| 97161 | <1% | 2,583 | $142K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,724 | $140K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 828 | $132K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 3,551 | $131K |
| 97162 | <1% | 2,639 | $129K | |
| 73564 | <1% | 1,627 | $120K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 6,106 | $119K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 49,629 | $118K |
| 93976 | <1% | 944 | $101K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 511 | $94K |
| 76830 | Ultrasound, transvaginal | <1% | 1,008 | $91K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 5,060 | $91K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 523 | $89K |
| 72197 | <1% | 294 | $88K | |
| 86900 | <1% | 4,080 | $88K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,142 | $87K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 768 | $84K |
| 72100 | <1% | 1,805 | $83K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,989 | $82K |
| 83718 | <1% | 12,673 | $82K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 56,915 | $72K |
| 82247 | <1% | 32,557 | $69K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 13,817 | $69K |
| 72141 | <1% | 277 | $66K | |
| 74183 | <1% | 413 | $65K | |
| 82947 | <1% | 37,201 | $64K | |
| 82040 | <1% | 33,112 | $61K | |
| 73610 | <1% | 1,612 | $60K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,623 | $59K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,350 | $57K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,223 | $53K |
| 73030 | <1% | 1,745 | $52K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 760 | $51K |
| 94060 | <1% | 276 | $51K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 621 | $51K |
| 76801 | <1% | 460 | $50K | |
| 86235 | <1% | 680 | $49K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 5,682 | $49K |
| 82607 | <1% | 6,155 | $48K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,264 | $48K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 342 | $47K |
| 73630 | <1% | 1,382 | $46K | |
| 71250 | <1% | 791 | $45K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 49 | $45K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,290 | $44K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 490 | $44K |
| 97035 | <1% | 582 | $42K | |
| 76536 | <1% | 571 | $39K | |
| 82728 | <1% | 6,165 | $37K | |
| 86480 | <1% | 1,249 | $37K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 3,549 | $36K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 487 | $35K |
| 86003 | <1% | 611 | $34K | |
| 73221 | <1% | 177 | $34K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 1,770 | $34K |
| 73502 | <1% | 1,209 | $33K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 342 | $32K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,030 | $31K |
| 87632 | <1% | 760 | $31K | |
| 0240U | <1% | 299 | $30K | |
| 90837 | Psychotherapy session, about an hour | <1% | 387 | $30K |
| 83970 | <1% | 1,431 | $30K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 313 | $29K |
| 84439 | <1% | 6,010 | $29K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 928 | $29K |
| 82310 | <1% | 37,234 | $29K | |
| 73560 | <1% | 1,900 | $28K | |
| 86780 | <1% | 2,546 | $27K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,414 | $26K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 47 | $26K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,455 | $26K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 9,081 | $25K |
| 83550 | <1% | 6,216 | $25K | |
| 93971 | <1% | 408 | $25K | |
| 93000 | <1% | 1,904 | $24K | |
| 86850 | <1% | 3,906 | $24K | |
| 82784 | <1% | 2,566 | $23K | |
| 86803 | <1% | 3,207 | $23K | |
| 73130 | <1% | 642 | $22K | |
| 85027 | <1% | 8,511 | $21K | |
| 87070 | <1% | 7,842 | $21K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 11,755 | $20K |
| 64483 | <1% | 27 | $20K | |
| 84403 | <1% | 1,554 | $20K | |
| 83540 | <1% | 6,564 | $20K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 142 | $20K |
| 73110 | <1% | 476 | $19K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 600 | $18K |
| 86901 | <1% | 4,083 | $17K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,365 | $17K |
| 72170 | <1% | 388 | $17K | |
| 97116 | <1% | 804 | $17K | |
| 87506 | <1% | 205 | $17K | |
| 86769 | <1% | 498 | $16K | |
| 86140 | <1% | 7,745 | $16K | |
| 81001 | <1% | 13,022 | $15K | |
| 87430 | <1% | 4,937 | $15K | |
| 96415 | <1% | 188 | $15K | |
| 86038 | <1% | 2,088 | $14K | |
| 97165 | <1% | 222 | $13K | |
| 93970 | <1% | 82 | $13K | |
| 82670 | <1% | 867 | $13K | |
| 90686 | <1% | 1,562 | $13K | |
| 72040 | <1% | 380 | $12K | |
| 87631 | <1% | 362 | $12K | |
| 82570 | <1% | 4,330 | $12K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,604 | $12K |
| 83001 | <1% | 1,126 | $12K | |
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | <1% | 98 | $12K |
| 83735 | <1% | 5,075 | $12K | |
| 83655 | <1% | 1,504 | $11K | |
| 82465 | <1% | 12,808 | $11K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 13 | $11K |
| 97166 | <1% | 167 | $10K | |
| 87340 | <1% | 2,130 | $10K | |
| 88142 | <1% | 1,647 | $10K | |
| 83002 | <1% | 980 | $10K | |
| 86618 | <1% | 1,394 | $10K | |
| 84153 | <1% | 1,421 | $10K | |
| 87077 | <1% | 3,591 | $10K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 849 | $10K |
| 81003 | <1% | 11,456 | $9K | |
| Q3014 | Telehealth originating site facility fee | <1% | 1,331 | $9K |
| 85610 | <1% | 7,796 | $9K | |
| 70486 | <1% | 127 | $9K | |
| 86706 | <1% | 1,487 | $8K | |
| 83690 | <1% | 6,172 | $8K | |
| 86039 | <1% | 1,290 | $8K | |
| 82043 | <1% | 2,572 | $8K | |
| 70498 | <1% | 43 | $8K | |
| 87186 | <1% | 2,769 | $8K | |
| 83880 | <1% | 934 | $8K | |
| 12001 | <1% | 44 | $7K | |
| 84702 | <1% | 2,401 | $7K | |
| 95076 | <1% | 13 | $7K | |
| 82746 | <1% | 907 | $7K | |
| 82374 | <1% | 37,084 | $7K | |
| 74018 | <1% | 185 | $7K | |
| 84480 | <1% | 1,066 | $7K | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 13 | $7K |
| 85652 | <1% | 5,314 | $7K | |
| 84484 | <1% | 9,122 | $7K | |
| 80061 | Lipid panel | <1% | 3,313 | $7K |
| 80197 | <1% | 708 | $6K | |
| 73140 | <1% | 265 | $6K | |
| 51798 | <1% | 1,223 | $6K | |
| 70491 | <1% | 28 | $6K | |
| 94726 | <1% | 110 | $6K | |
| 85730 | <1% | 4,015 | $6K | |
| 84478 | <1% | 12,908 | $6K | |
| 84270 | <1% | 445 | $6K | |
| 97163 | <1% | 105 | $6K | |
| 86225 | <1% | 758 | $6K | |
| 86160 | <1% | 391 | $6K | |
| 83516 | <1% | 563 | $5K | |
| 81513 | <1% | 118 | $5K | |
| J3490 | Unclassified drugs | <1% | 50,032 | $5K |
| 98968 | <1% | 183 | $5K | |
| 84703 | <1% | 4,206 | $5K | |
| 99218 | <1% | 38 | $5K | |
| 81025 | <1% | 2,931 | $5K | |
| 72156 | <1% | 13 | $5K | |
| 92526 | <1% | 52 | $5K | |
| 86364 | <1% | 631 | $5K | |
| 84146 | <1% | 440 | $4K | |
| 90715 | <1% | 949 | $4K | |
| 82785 | <1% | 444 | $4K | |
| 83525 | <1% | 516 | $4K | |
| 72082 | <1% | 53 | $4K | |
| 85007 | <1% | 3,508 | $4K | |
| 85055 | <1% | 522 | $4K | |
| 20553 | <1% | 18 | $4K | |
| 93351 | <1% | 32 | $4K | |
| 96376 | <1% | 2,333 | $4K | |
| 94010 | <1% | 31 | $3K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 192 | $3K |
| 84156 | <1% | 1,558 | $3K | |
| 86704 | <1% | 477 | $3K | |
| 87481 | <1% | 106 | $3K | |
| 82627 | <1% | 186 | $3K | |
| 85046 | <1% | 1,115 | $3K | |
| 70496 | <1% | 108 | $3K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,264 | $3K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 236 | $3K |
| 85379 | <1% | 1,964 | $2K | |
| 86431 | <1% | 829 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,561 | $2K |
| 98967 | <1% | 102 | $2K | |
| 87040 | <1% | 2,642 | $2K | |
| 73522 | <1% | 28 | $2K | |
| 59025 | Fetal non-stress test | <1% | 26 | $2K |
| 93017 | <1% | 56 | $2K | |
| 80143 | <1% | 1,099 | $2K | |
| 84145 | <1% | 729 | $2K | |
| 86376 | <1% | 226 | $2K | |
| 80179 | <1% | 1,103 | $2K | |
| 77065 | Tomosynthesis, mammo | <1% | 15 | $2K |
| 86708 | <1% | 287 | $2K | |
| 87807 | <1% | 316 | $2K | |
| 84305 | <1% | 117 | $2K | |
| 90662 | <1% | 285 | $2K | |
| 76642 | <1% | 24 | $2K | |
| 85018 | <1% | 2,482 | $2K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 4,464 | $2K |
| 85014 | <1% | 2,434 | $2K | |
| 93320 | <1% | 93 | $2K | |
| 88304 | <1% | 320 | $2K | |
| 86200 | <1% | 233 | $2K | |
| 87205 | <1% | 1,488 | $1K | |
| 77080 | <1% | 12 | $1K | |
| 86709 | <1% | 268 | $1K | |
| 82550 | <1% | 1,484 | $1K | |
| 84481 | <1% | 151 | $1K | |
| 87075 | <1% | 700 | $1K | |
| 84450 | <1% | 32,904 | $1K | |
| 86800 | <1% | 150 | $1K | |
| 82248 | <1% | 4,097 | $1K | |
| 83605 | <1% | 1,306 | $1K | |
| 87338 | <1% | 92 | $1K | |
| 86762 | <1% | 184 | $1K | |
| 77072 | <1% | 17 | $1K | |
| 0054A | <1% | 70 | $920.00 | |
| 84165 | <1% | 238 | $837.02 | |
| 82962 | <1% | 6,727 | $831.51 | |
| 83520 | <1% | 116 | $828.12 | |
| 82533 | <1% | 106 | $796.79 | |
| 76870 | <1% | 31 | $766.56 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 18 | $765.86 |
| 82378 | <1% | 156 | $764.27 | |
| 64450 | <1% | 12 | $731.95 | |
| 72070 | <1% | 13 | $711.66 | |
| 73590 | <1% | 30 | $695.33 | |
| 84100 | <1% | 3,064 | $686.33 | |
| 86360 | <1% | 25 | $680.34 | |
| 99442 | <1% | 188 | $659.93 | |
| 73070 | <1% | 26 | $646.54 | |
| 93325 | <1% | 144 | $635.57 | |
| 84075 | <1% | 32,650 | $625.51 | |
| 83021 | <1% | 99 | $620.64 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 24 | $554.17 |
| 86334 | <1% | 74 | $553.91 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,592 | $466.97 |
| 86308 | <1% | 122 | $452.35 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 6,835 | $439.18 |
| 90732 | <1% | 13 | $431.00 | |
| 82105 | <1% | 52 | $429.05 | |
| 84436 | <1% | 145 | $425.54 | |
| 84520 | <1% | 37,623 | $409.43 | |
| 84550 | <1% | 2,268 | $393.64 | |
| 83615 | <1% | 1,853 | $382.45 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,377 | $381.77 |
| 84460 | <1% | 32,997 | $379.54 | |
| 86258 | <1% | 18 | $374.68 | |
| 88342 | <1% | 230 | $330.65 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 754 | $329.47 |
| 82565 | <1% | 37,872 | $323.57 | |
| 74019 | <1% | 27 | $290.11 | |
| 87046 | <1% | 27 | $288.64 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 141 | $287.80 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 960 | $283.23 |
| 84155 | <1% | 33,031 | $281.13 | |
| 86765 | <1% | 56 | $258.51 | |
| 84132 | <1% | 37,025 | $256.28 | |
| 76376 | <1% | 445 | $250.36 | |
| 84295 | <1% | 37,142 | $240.25 | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 378 | $208.79 |
| 82435 | <1% | 37,086 | $202.26 | |
| 86580 | <1% | 17 | $180.18 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,662 | $176.96 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,421 | $173.17 |
| 83521 | <1% | 13 | $173.04 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 167 | $169.96 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,234 | $163.77 |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 461 | $159.01 |
| 86705 | <1% | 39 | $157.50 | |
| 82977 | <1% | 558 | $142.05 | |
| 86300 | <1% | 15 | $139.09 | |
| 82397 | <1% | 13 | $134.90 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 521 | $131.33 |
| 87045 | <1% | 39 | $126.28 | |
| 95012 | <1% | 177 | $120.59 | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 483 | $108.00 |
| 86304 | <1% | 14 | $79.48 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,929 | $74.07 |
| 86787 | <1% | 13 | $73.86 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,965 | $71.81 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,137 | $71.44 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 693 | $70.25 |
| 69210 | <1% | 39 | $62.77 | |
| 84144 | <1% | 17 | $59.76 | |
| 82523 | <1% | 15 | $53.55 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 489 | $52.25 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,362 | $46.86 |
| 82270 | <1% | 13 | $40.43 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,614 | $36.90 |
| 84300 | <1% | 18 | $32.93 | |
| 80178 | <1% | 15 | $32.28 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 59 | $31.71 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 49 | $30.30 |
| 81002 | <1% | 960 | $26.84 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,337 | $23.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 22 | $19.56 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 950 | $15.66 |
| 99441 | <1% | 13 | $11.14 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 19 | $7.71 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 96 | $7.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 279 | $6.41 |
| 87081 | <1% | 13 | $6.34 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 285 | $2.15 |
| G0008 | Administration of influenza virus vaccine | <1% | 118 | $2.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,005 | $1.80 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 227 | $1.67 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,649 | $1.05 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 4,377 | $0.36 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 2,432 | $0.01 |
| 99153 | Mod sedat endo service >5yrs | 0% | 1,038 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 1,340 | $0.00 |
| 94760 | 0% | 952 | $0.00 | |
| 92060 | 0% | 268 | $0.00 | |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 993 | $0.00 |
| 88300 | 0% | 292 | $0.00 | |
| J7999 | Compounded drug, not otherwise classified | 0% | 331 | $0.00 |
| 76377 | 0% | 69 | $0.00 | |
| J3535 | Drug administered through a metered dose inhaler | 0% | 17 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 126 | $0.00 |
| 91305 | 0% | 70 | $0.00 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 17 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 59 | $0.00 |
| 91307 | 0% | 12 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 253 | $0.00 |
| 99152 | 0% | 1,097 | $0.00 | |
| C1776 | Joint device (implantable) | 0% | 70 | $0.00 |
| 94729 | 0% | 218 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 174 | $0.00 |
| 93356 | 0% | 15 | $0.00 | |
| 90461 | 0% | 337 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 129 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 24 | $0.00 |
| 00812 | 0% | 17 | $0.00 | |
| 98966 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWRINN, JACQUELINE (DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Yale New Haven Hospital | New Haven, CT | $1.08B |
| Bridgeport Hospital | Bridgeport, CT | $287.34M |
| Lawrence and Memorial Hospital, INC. | New London, CT | $136.19M |
| Bridgeport Hospital | Milford, CT | $15.60M |
| LMW Healthcare INC. | Westerly, RI | $13.10M |
| Lawrence and Memorial Hospital, INC. | New London, CT | $1.55M |
| Yale New Haven Hospital | New Haven, CT | $629K |
| LMW Healthcare INC. | Westerly, RI | $492K |
| Bridgeport Hospital | Bridgeport, CT | $398K |
| Lawrence and Memorial Hospital, INC. | New London, CT | $365K |
| Shoreline Endoscopy Center, LLC | Guilford, CT | $19K |
| Yale New Haven Hospital | New Haven, CT | $860.83 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.